新型PSMA靶向放射性药物[68Ga]Ga/[177Lu]Lu-NYM032用于前列腺癌诊疗一体化的初步评价
本研究开发了靶向前列腺特异性膜抗原(PSMA)的新型诊疗一体化放射性药物[68Ga]Ga/[177Lu]Lu-NYM032,先在LNCaP模型评估诊断效能,再在10例前列腺癌患者中与[68Ga]Ga-PSMA617对比,最后在LNCaP模型评估[177Lu]Lu-NYM032的治疗潜力。结果显示该药物耐受良好,[68Ga]Ga-NYM032在骨转移灶摄取显著高于[68Ga]Ga-PSMA617,[177Lu]Lu-NYM032可抑制肿瘤进展且疗效随放射性剂量增加而增强。
要点
- 临床前和临床研究中[68Ga]Ga/[177Lu]Lu-NYM032耐受良好,未观察到不良事件。
- 骨转移灶中[68Ga]Ga-NYM032摄取中位数5.10显著高于[68Ga]Ga-PSMA617的3.88(P < 0.001,n = 48)。
- 高放射性剂量组(74 MBq/小鼠)第21天肿瘤体积107.14 ± 13.68 mm3显著小于空白对照组1351.86 ± 249.98 mm3(P < 0.001,n = 7)。
核心结论
- [68Ga]Ga/[177Lu]Lu-NYM032作为新型强效诊疗一体化放射性药物用于前列腺癌具有相当大的潜力。
研究设计与样本
- 开发靶向PSMA的新型诊疗一体化放射性药物[68Ga]Ga/[177Lu]Lu-NYM032,并初步评价其在前列腺癌诊断和治疗中的潜力。
- 先在PSMA阳性荷瘤模型(LNCaP模型)中评估PET示踪剂[68Ga]Ga-NYM032的诊断效能,随后在10例前列腺癌患者中以[68Ga]Ga-PSMA617作为对照进行比较。
- 最后在LNCaP模型中评估[177Lu]Lu-NYM032的治疗潜力。
- 本研究的临床评价已于2024年4月29日在Clinicaltrial.gov注册(NCT06389695)。
主要发现
- [68Ga]Ga/[177Lu]Lu-NYM032耐受良好,临床前和临床研究中未观察到不良事件。
- [68Ga]Ga-NYM032表现出PSMA特异性,在LNCaP肿瘤中放射性摄取高。
- 同一原位病灶同一注射后时间点,[68Ga]Ga-NYM032摄取(SUVmax)与[68Ga]Ga-PSMA617摄取无显著差异(中位数9.40 vs. 6.85,P = 0.123,n = 8)。
- 与[68Ga]Ga-PSMA617摄取相比,[68Ga]Ga-NYM032在骨转移灶中摄取显著更高(中位数5.10 vs. 3.88,P < 0.001,n = 48),在淋巴结转移灶中更高(中位数7.81 vs. 5.46,n = 2)。
- [177Lu]Lu-NYM032在LNCaP模型病灶中聚集高、滞留时间长,可抑制肿瘤进展,且治疗效率随放射性剂量(18.5-74 MBq/小鼠)增加而增强;高放射性剂量治疗组(74 MBq/小鼠)第21天肿瘤体积显著小于空白对照组(107.14 ± 13.68 mm3 vs. 1351.86 ± 249.98 mm3,P < 0.001,n = 7)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A novel theranostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), [68Ga]Ga/[177Lu]Lu-NYM032, was developed and its diagnostic and therapeutic potential in the treatment of prostate cancer (PCa) was preliminarily evaluated. METHODS: The diagnostic efficacy of the PET tracer [68Ga]Ga-NYM032 was first evaluated in PSMA-positive xenograft-bearing models (LNCaP models), followed by evaluation in 10 PCa patients using [68Ga]Ga-PSMA617 a comparator. Finally, the therapeutic potential of [177Lu]Lu-NYM032 was evaluated in LNCaP models. RESULTS: [68Ga]Ga/[177Lu]Lu-NYM032 was well-tolerated, and no adverse events were observed in the preclinical and clinical studies. [68Ga]Ga-NYM032 demonstrated PSMA specificity and high radioactive uptake in LNCaP tumors. [68Ga]Ga-NYM032 uptake (SUVmax) did not differ from [68Ga]Ga-PSMA617 uptake in the same in situ lesions at the same p.i. time point (median 9.40 vs. 6.85, P = 0.123, n = 8). Compared with [68Ga]Ga-PSMA617 uptake, [68Ga]Ga-NYM032 uptake was significantly higher in osseous metastases (median 5.10 vs. 3.88, P < 0.001, n = 48), and higher in lymph node metastases (median 7.81 vs. 5.46, n = 2). [177Lu]Lu-NYM032 showed high aggregation in the lesions of LNCaP models and long retention times. [177Lu]Lu-NYM032 could inhibit tumor progression in LNCaP models, and its therapeutic efficiency strengthened with increasing radio-dosage (18.5-74 MBq/mouse). The tumor volume in the high radio-dosage treatment group (74 MBq/mouse) was significantly smaller than that in the blank control group at 21 days p.i. (107.14 ± 13.68 mm3 vs. 1351.86 ± 249.98 mm3, P < 0.001, n = 7). CONCLUSION: [68Ga]Ga/[177Lu]Lu-NYM032 has considerable potential as a novel and powerful theranostic radiopharmaceutical for PCa. TRIAL REGISTRATION: The clinical evaluation of this study was registered at Clinicaltrial.gov (NCT06389695) on 29 Apr, 2024.
引用
- Fu H, He H, Wang Y, et al. Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga/[177Lu]Lu-NYM032 for theranostic use in prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 39745526. doi:10.1007/s00259-024-07046-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。